MTOR and autoimmune lymphoproliferative syndrome: In autoimmune lymphoproliferative syndrome (ALPS) patients carrying mutations in FAS (ALPS‐FAS), we detected increased PI3K/AKT/mTOR activity in tissue‐resident B cells and an enhanced EF response [2], concomitant with strongly reduced GCs [2, 85].